|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||Yusuf, R, Saez, B, Sharda, A, van Gastel, N, Yu, V, Baryawno, N, Scadden, EW, Acharya, SS, Chattophadhyay, S, Huang, C, Viswanathan, V, S'aulis, D, Cobert, J, Sykes, DBrian, Keibler, MA, Das, S, Hutchinson, JN, Churchill, M, Mukherjee, S, Lee, D, Mercier, FEmile, Doench, J, Bullinger, L, Logan, DJ, Schreiber, S, Stephanopoulos, G, Rizzo, WB, Scadden, DT|
|Date Published||2020 May 26|
Metabolic alterations in cancer represent convergent effects of oncogenic mutations. We hypothesized that a metabolism-restricted genetic screen, comparing normal primary mouse hematopoietic cells and their malignant counterparts in an ex vivo system mimicking the bone marrow microenvironment, would define distinctive vulnerabilities in acute myeloid leukemia (AML). Leukemic cells, but not their normal myeloid counterparts, depended on the aldehyde dehydrogenase 3a2 (Aldh3a2) enzyme that oxidizes long-chain aliphatic aldehydes to prevent cellular oxidative damage. Aldehydes are by-products of increased oxidative phosphorylation and nucleotide synthesis in cancer and generated from lipid peroxides underlying the non-caspase dependent form of cell death, ferroptosis. Leukemic cell dependence on Aldh3a2 was seen across multiple mouse and human myeloid leukemias. Aldh3a2 inhibition was synthetically lethal with glutathione peroxidase-4 (GPX4) inhibition, a known trigger of ferroptosis that by itself minimally affects AML cells. Inhibiting Aldh3a2 provides a therapeutic opportunity and a unique synthetic lethality to exploit the distinctive metabolic state of malignant cells.